Total PSA optimal range and reference range
Compiled by Alina Radu, founder of Sera, from the published sources below · Last reviewed November 9, 2026
Sera's bands for Total PSA:
- Optimal 0 – 2.5 ng/mL (0 – 2.5 μg/L); sufficient 2.5 – 4 ng/mL (2.5 – 4 μg/L); out of range below 0 or above 4 ng/mL.
Evidence grade: Established clinical threshold. A band edge that corresponds to a recognised diagnostic, risk or treatment threshold from a major clinical guideline or public-health body.
All units
| Unit | Optimal | Sufficient | Out of range |
|---|---|---|---|
| ng/mL | 0 – 2.5 | 2.5 – 4 | below 0 or above 4 |
| μg/L | 0 – 2.5 | 2.5 – 4 | below 0 or above 4 |
What the evidence says
The acceptable band ends at 4.0 ng/mL, the cutoff the US National Cancer Institute describes as generally abnormal and the upper limit of common laboratory reference intervals. It is a long-standing convention rather than a boundary between health and disease: cancer occurs below it and most men above it do not have it. The optimal band ending at 2.5 ng/mL is not an outcome-based target; 2.5 is the lower cutoff some doctors use for younger men and the NICE referral threshold for men aged 40 to 49. UK practice is age-specific (above 3.5 at 50 to 59, 4.5 at 60 to 69, 6.5 at 70 to 79) or 3 ng/mL at any age in the screening-programme guidance, so a man in his 60s or 70s can be above 4.0 and still under his age threshold. Benign enlargement, prostatitis or a urine infection, recent ejaculation, vigorous exercise such as cycling and a digital examination can raise it; finasteride and dutasteride lower it, conventionally by about half, so double the result on either. A trend across draws beats any single value.
Sources
- Prostate-Specific Antigen (PSA) Test — National Cancer Institute (NIH), 2025 · Government / public-health guidanceA PSA above 4.0 ng/mL is generally considered abnormal and may lead to a biopsy recommendation; some doctors use a lower cutoff such as 2.5 ng/mL for younger men and a higher one such as 5 for older men. There is no single threshold separating normal from abnormal. Matches Sera's sufficient upper 4.0 and names the 2.5 figure used as the optimal upper.
- Screening Tests for Prostate Cancer — American Cancer Society, 2023 · Professional societyMany doctors use 4 ng/mL as the cutoff for further testing, others start at 2.5 or 3. Most men without prostate cancer are under 4; between 4 and 10 the chance of cancer is about 1 in 4, above 10 it is over 50%. A level below 4 does not rule cancer out.
- Prostate Specific Antigen, Total with Reflex to Free PSA (Includes Free Percentage) — ARUP Laboratories, 2026 · Laboratory / reference-interval sourceARUP's laboratory reference interval for total PSA is 0.0 to 4.0 ng/mL; free PSA is added when the total is 3.0 to 10.0 ng/mL. Matches Sera's sufficient band of 0 to 4. Test directory page as opened in October 2026; the page carries no publication date.
- Diagnosis of prostate cancer in primary care: navigating updated clinical guidance — Merriel SWD, Seggie A, Ahmed H — The British Journal of General Practice, 2023 · Peer-reviewed publicationReproduces the NICE NG12 (2021 update) referral thresholds for men with possible symptoms: above 2.5 micrograms/L at 40 to 49, 3.5 at 50 to 59, 4.5 at 60 to 69, 6.5 at 70 to 79, clinical judgement outside those ages. Also states the UK Prostate Cancer Risk Management Programme uses 3 ng/mL regardless of age. Shows 2.5 is the UK threshold for men in their 40s, and that UK practice does not use a flat 4.0. Full text read through the Europe PMC full-text service for PMC9888566.
- Prostate-Specific Antigen (PSA) Test: MedlinePlus Medical Test — MedlinePlus, US National Library of Medicine, 2025 · Government / public-health guidanceStates that no specific PSA level is normal or abnormal and gives no numeric cutoff. Supports the note's statement that 4.0 is a convention, not a boundary between health and disease; it does not support any band edge.
What PSA (Total) measures
Prostate-specific antigen, a protein made by the prostate and measurable in the blood of anyone who has one.
Prostate-specific, not cancer-specific: benign enlargement, prostatitis, a recent ejaculation, cycling and a digital examination all raise it, and finasteride roughly halves it. The 4.0 ng/mL threshold is a convention rather than a boundary between health and disease, and age-adjusted cut-offs run lower in younger men. A rising trend across draws is more informative than any single value.